Moberg Pharma — Share Issue/Capital Change 2022

Apr 29, 2022

PRESS RELEASE

New number of shares and votes in Moberg Pharma AB (publ)

STOCKHOLM, April 29th, 2022, Moberg Pharma AB (OMX: MOB) announced that the total number of common shares in the company has increased to 46,681,123 due to the completion of the previously announced exercise of warrants of series 2020:1.

During April 2022, the total number of shares and votes in the company has increased by 1,169,698, corresponding to 1,169,698 votes. As per April 29th, 2022, the last trading day in April, the total number of shares in Moberg Pharma AB (publ) amounts to 46,681,123. All shares are common shares. The total number of votes are 46,681,123. At the date of this press release, the Company holds 1,464,746 own common shares.

For additional information, please contact:

Anna Ljung, CEO, telephone: +46 707 66 60 30, e-mail: anna.ljung@mobergpharma.se Mark Beveridge, VP Finance, telephone: +46 76 - 805 82 88, e-mail: mark.beveridge@mobergpharma.se

About this information

The above information has been made public in accordance with the Swedish Financial Instruments Trading Act. The information was released for public distribution on April 29th, 2022, at 8:00 am CEST.

About Moberg Pharma, www.mobergpharma.se

Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company's main asset, MOB-015, is a novel topical treatment for onychomycosis. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in Europe and Japan, among others, and the Company's goal is to receive its first market approval and launch MOB-015 in 2023. Moberg Pharma is headquartered in Stockholm and the Company's shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).